Baricitinib and primary biliary cholangitis

Kaplan, 2005, Primary biliary cirrhosis, N. Engl. J. Med., 353, 1261, 10.1056/NEJMra043898 Lindor, 2009, Primary biliary cirrhosis, Hepatology, 50, 291, 10.1002/hep.22906 Kuiper, 2009, Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid, Gastroenterology, 136, 1281, 10.1053/j.gastro.2009.01.003 Pares, 2006, Excellent long‐term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid, Gastroenterology, 130, 715, 10.1053/j.gastro.2005.12.029 Corpechot, 2008, Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis, Hepatology, 48, 871, 10.1002/hep.22428 Hirschfield, 2015, Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid, Gastroenterology, 148, 751, 10.1053/j.gastro.2014.12.005 2016 Dyson, 2016, The inter‐relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis, Aliment. Pharmacol. Ther., 44, 1039, 10.1111/apt.13794 Fuchs, 2017, Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis, Clin. Liver Dis., 9, 43, 10.1002/cld.613 Papp, 2016, A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis, Br. J. Dermatol., 174, 1266, 10.1111/bjd.14403 Blome, 2012, Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus, Acta Derm. Venereol., 92, 502, 10.2340/00015555-1246 Neuberge, 2003, Measures of fatigue: the fatigue questionnaire, fatigue severity scale, multidimensional assessment of fatigue scale, and short form‐36 vitality (Energy/Fatigue) subscale of the short form Health survey, Arthritis Rheum., 49, S175, 10.1002/art.11405 Phan, 2012, Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus, Acta Derm. Venereol., 92, 502, 10.2340/00015555-1246 Lichtinghagen, 2013, The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values, J. Hepatol., 59, 236, 10.1016/j.jhep.2013.03.016 Rush, 2003, The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression, Biol. Psychiatr., 54, 573, 10.1016/S0006-3223(02)01866-8 Hirschfield, 2009, Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants, N. Engl. J. Med., 360, 2544, 10.1056/NEJMoa0810440 Kawata, 2013, Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis, PloS One, 8, 10.1371/journal.pone.0074225 Fridman, 2010, Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050, J. Immunol., 184, 5298, 10.4049/jimmunol.0902819 O'Shea, 2015, The JAK-STAT pathway: impact on human disease and therapeutic intervention, Annu. Rev. Med., 66, 311, 10.1146/annurev-med-051113-024537 O'Shea, 2013, Janus kinase inhibitors in autoimmune diseases, Ann. Rheum. Dis., 72, ii111, 10.1136/annrheumdis-2012-202576 Poupon, 1996, Primary biliary cirrhosis, 1329